Immunogenicity analysis following human immunodeficiency virus recombinant DNA and recombinant vaccinia virus Tian Tan prime-boost immunization

Liu, CunXia; Du, Shouwen; Chang, Li; Wang, Yuhang; Wang, MaoPeng; Li, Yi; Yin, Rong; Li, Xiao; Ren, Dayong; Qin, Yan-Qing; Ren, Jin; Jin, Ningyi

doi:10.1007/s11427-013-4484-2

Cited by 9 publications

(6 citation statements)

References 50 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The splenocytes were isolated from immunized mice at the end of the experiment according to the previously described protocol ( Liu et al., 2013 ; Xu et al., 2021 ). Briefly, the mouse spleen was homogenized and suspended in Roswell Park Memorial Institute (RPMI) 1640 (Hyclone, Beijing, China) to prepare cell suspension.…”

Section: Methodsmentioning

confidence: 99%

Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins

Chen

Wang²,

Li³

et al. 2022

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), has posed a constant threat to human beings and the world economy for more than two years. Vaccination is the first choice to control and prevent the pandemic. However, an effective SARS-CoV-2 vaccine against the virus infection is still needed. This study designed and prepared four kinds of virus-like particles (VLPs) using an insect expression system. Two constructs encoded wild-type SARS-CoV-2 spike (S) fused with or without H5N1 matrix 1 (M1) (S and SM). The other two constructs contained a codon-optimized spike gene and/or M1 gene (mS and mSM) based on protein expression, stability, and ADE avoidance. The results showed that the VLP-based vaccine could induce high SARS-CoV-2 specific antibodies in mice, including specific IgG, IgG1, and IgG2a. Moreover, the mSM group has the most robust ability to stimulate humoral immunity and cellular immunity than the other VLPs, suggesting the mSM is the best immunogen. Further studies showed that the mSM combined with Al/CpG adjuvant could stimulate animals to produce sustained high-level antibodies and establish an effective protective barrier to protect mice from challenges with mouse-adapted strain. The vaccine based on mSM and Al/CpG adjuvant is a promising candidate vaccine to prevent the COVID-19 pandemic.

show abstract

Section: Methodsmentioning

confidence: 99%

Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins

Chen

Wang²,

Li³

et al. 2022

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Other replication-competent viruses in clinical development include the TianTan vaccinia virus (TT), Vesicular stomatitis virus (VSV), a derivative of NYVAC (NYVAC-C-KC) and Sendai virus (SeV). The TianTan vaccinia virus was used in a DNA-prime (pCCMp24)/Tiantan boost (rddVTT-CCMp24) regimen where it was shown to induce antibody and HIV-specific T cell responses (including memory phenotypes) following intramuscular delivery and has now been advanced to Phase II clinical study in China (Excler et al, 2010; Liu et al, 2013). The NYVAC-C-KC vectors have shown superior cellular and humoral immunity compared to the non-replicating NYVAC, at least in mice (Kibler et al, 2011; Gomez et al, 2012).…”

Section: Replication-competent Viral Vectorsmentioning

confidence: 99%

“…Undoubtedly, repeated immunizations or combining DNA vaccines with persistent (replicating) vectors or vectors with slow immunogen release features would induce durable immunity. Nonetheless, replicating vectors with lower sero-prevalence and minimal pathogenicity (Rose et al, 2001; Kawada et al, 2007; Fuchs et al, 2013; Liu et al, 2013) are being considered as they would provide a persistent pool of HIV vaccine-specific effector memory phenotype cytotoxic T cells which are critical for long-term protection from disease progression (Hansen et al, 2009, 2011, 2013). Such effector memory responses would otherwise be expected to wane with time, in the absence of antigen.…”

Section: Perspectives and Conclusionmentioning

confidence: 99%

The influence of delivery vectors on HIV vaccine efficacy

Ondondo

2014

Front. Microbiol.

View full text Add to dashboard Cite

Development of an effective HIV/AIDS vaccine remains a big challenge, largely due to the enormous HIV diversity which propels immune escape. Thus novel vaccine strategies are targeting multiple variants of conserved antibody and T cell epitopic regions which would incur a huge fitness cost to the virus in the event of mutational escape. Besides immunogen design, the delivery modality is critical for vaccine potency and efficacy, and should be carefully selected in order to not only maximize transgene expression, but to also enhance the immuno-stimulatory potential to activate innate and adaptive immune systems. To date, five HIV vaccine candidates have been evaluated for efficacy and protection from acquisition was only achieved in a small proportion of vaccinees in the RV144 study which used a canarypox vector for delivery. Conversely, in the STEP study (HVTN 502) where human adenovirus serotype 5 (Ad5) was used, strong immune responses were induced but vaccination was more associated with increased risk of HIV acquisition than protection in vaccinees with pre-existing Ad5 immunity. The possibility that pre-existing immunity to a highly promising delivery vector may alter the natural course of HIV to increase acquisition risk is quite worrisome and a huge setback for HIV vaccine development. Thus, HIV vaccine development efforts are now geared toward delivery platforms which attain superior immunogenicity while concurrently limiting potential catastrophic effects likely to arise from pre-existing immunity or vector-related immuno-modulation. However, it still remains unclear whether it is poor immunogenicity of HIV antigens or substandard immunological potency of the safer delivery vectors that has limited the success of HIV vaccines. This article discusses some of the promising delivery vectors to be harnessed for improved HIV vaccine efficacy.

show abstract

“…Vaccinia virus (VACV) has had an important role in human history due to its use as a vaccine during the smallpox vaccination campaign, resulting in the eradication of this deadly disease in 1980 [ 1 ]. More recently, VACV has been widely used as a vector for recombinant vaccines [ 2 , 3 , 4 ]. Following Smallpox eradication, other zoonotic orthopoxviruses (OPV) have emerged worldwide, such as Cowpox virus (CPXV), in Europe, Monkeypox virus (MPXV), endemic in many African countries and recently introduced in the USA, and finally VACV, endemic in Brazil and India [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

From Lesions to Viral Clones: Biological and Molecular Diversity amongst Autochthonous Brazilian Vaccinia Virus

Oliveira

Assis

Almeida

et al. 2015

Viruses

View full text Add to dashboard Cite

Vaccinia virus (VACV) has had an important role for humanity because of its use during the smallpox eradication campaign. VACV is the etiologic agent of the bovine vaccinia (BV), an emerging zoonosis that has been associated with economic, social, veterinary and public health problems, mainly in Brazil and India. Despite the current and historical VACV importance, there is little information about its circulation, prevalence, origins and maintenance in the environment, natural reservoirs and diversity. Brazilian VACV (VACV-BR) are grouped into at least two groups based on genetic and biological diversity: group 1 (G1) and group 2 (G2). In this study, we went to the field and investigated VACV clonal diversity directly from exanthemous lesions, during BV outbreaks. Our results demonstrate that the G1 VACV-BR were more frequently isolated. Furthermore, we were able to co-detect the two variants (G1 and G2) in the same sample. Molecular and biological analysis corroborated previous reports and confirmed the co-circulation of two VACV-BR lineages. The detected G2 clones presented exclusive genetic and biological markers, distinct to reference isolates, including VACV-Western Reserve. Two clones presented a mosaic profile, with both G1 and G2 features based on the molecular analysis of A56R, A26L and C23L genes. Indeed, some SNPs and INDELs in A56R nucleotide sequences were observed among clones of the same virus population, maybe as a result of an increased mutation rate in a mixed population. These results provide information about the diversity profile in VACV populations, highlighting its importance to VACV evolution and maintenance in the environment.

show abstract

Immunogenicity analysis following human immunodeficiency virus recombinant DNA and recombinant vaccinia virus Tian Tan prime-boost immunization

Cited by 9 publications

References 50 publications

Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins

Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins

The influence of delivery vectors on HIV vaccine efficacy

From Lesions to Viral Clones: Biological and Molecular Diversity amongst Autochthonous Brazilian Vaccinia Virus

Contact Info

Product

Resources

About